ArticlebioRxiv : the preprint server for biology2023
Therapeutic targeting of immunometabolism in Alzheimer's disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression.
Juan F Codocedo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.